Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115857) titled 'Regulation of NRF2/HMOX-1/GPX4 Signaling Pathway by She Ethnic Medicine Shiliang Tea Inhibits Ferroptosis and Attenuates Non-alcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus: Clinical Application and Mechanistic Study' on Dec. 31, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Lishui People's Hospital
Condition:
Non-alcoholic fatty liver disease with type 2 diabetes mellitus
Intervention:
Control group:Standard therapy with metformin (Glucophage) 0.5 g, orally, one tablet twice daily
dosage adjusted according to blood glucose levels
Recruitment Status: Not Recrui...